Table 2.
Survival Estimates for OS, RFS, and DRFS According to Patient Characteristics Among Patients With Stage I to III BC Diagnosed Between 1997 and 2011 and Treated With Adjuvant Chemotherapy
| Characteristic | No. of Patients | No. of Events | 5-Year OS | 95% CI | P | No. of Events | 5-Year RFS | 95% CI | P | No. of Events | 5-Year DRFS | 95% CI | P |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All patients | 6,827 | 1,437 | 0.84 | 0.83 to 0.85 | 2,135 | 0.69 | 0.67 to 0.70 | 1,924 | 0.72 | 0.71 to 0.73 | .74 | ||
| TTC, days | .54 | .67 | .49 | ||||||||||
| ≤ 30 | 2,716 | 553 | 0.85 | 0.83 to 0.86 | 839 | 0.69 | 0.67 to 0.71 | 756 | 0.73 | 0.71 to 0.75 | |||
| 31-60 | 2,994 | 634 | 0.83 | 0.82 to 0.85 | 930 | 0.69 | 0.67 to 0.71 | 833 | 0.72 | 0.70 to 0.74 | |||
| ≥ 61 | 1,117 | 250 | 0.83 | 0.81 to 0.86 | 366 | 0.68 | 0.65 to 0.71 | 335 | 0.71 | 0.68 to 0.74 | |||
| Race/ethnicity | < .001 | .01 | .017 | ||||||||||
| White | 4,927 | 1,065 | 0.84 | 0.83 to 0.85 | 1,608 | 0.68 | 0.66 to 0.69 | 1,452 | 0.71 | 0.70 to 0.73 | |||
| African American | 646 | 172 | 0.80 | 0.76 to 0.84 | 207 | 0.68 | 0.63 to 0.72 | 186 | 0.70 | 0.66 to 0.74 | |||
| Hispanic | 912 | 160 | 0.86 | 0.83 to 0.89 | 230 | 0.74 | 0.71 to 0.77 | 206 | 0.77 | 0.74 to 0.8 | |||
| Other | 342 | 40 | 0.90 | 0.85 to 0.93 | 90 | 0.74 | 0.68 to 0.79 | 80 | 0.78 | 0.72 to 0.83 | |||
| Pathologic tumor size | < .001 | < .001 | < .001 | ||||||||||
| T1 | 3,643 | 533 | 0.90 | 0.89 to 0.91 | 813 | 0.78 | 0.76 to 0.80 | 702 | 0.82 | 0.80 to 0.83 | |||
| T2 | 2,642 | 715 | 0.78 | 0.76 to 0.80 | 1,069 | 0.59 | 0.57 to 0.61 | 989 | 0.62 | 0.60 to 0.64 | |||
| T3-4 | 448 | 156 | 0.70 | 0.65 to 0.75 | 198 | 0.50 | 0.45 to 0.56 | 184 | 0.54 | 0.48 to 0.60 | |||
| Pathologic nodal status | < .001 | < .001 | < .001 | ||||||||||
| N0 | 2,804 | 429 | 0.88 | 0.86 to 0.89 | 672 | 0.76 | 0.74 to 0.78 | 574 | 0.79 | 0.78 to 0.81 | |||
| N1 | 2,539 | 485 | 0.86 | 0.85 to 0.88 | 757 | 0.70 | 0.68 to 0.72 | 686 | 0.74 | 0.72 to 0.76 | |||
| N2 | 872 | 265 | 0.78 | 0.75 to 0.81 | 368 | 0.57 | 0.53 to 0.61 | 346 | 0.60 | 0.56 to 0.64 | |||
| N3 | 506 | 221 | 0.66 | 0.61 to 0.71 | 275 | 0.47 | 0.42 to 0.52 | 262 | 0.50 | 0.45 to 0.55 | |||
| Breast cancer subtype | < .001 | < .001 | < .001 | ||||||||||
| Hormone receptor–positive | 3,834 | 604 | 0.88 | 0.87 to 0.90 | 1,005 | 0.73 | 0.72 to 0.75 | 921 | 0.76 | 0.75 to 0.78 | |||
| HER2-positive | 1,142 | 261 | 0.81 | 0.78 to 0.84 | 368 | 0.64 | 0.61 to 0.68 | 333 | 0.68 | 0.65 to 0.71 | |||
| Triple-negative | 889 | 299 | 0.65 | 0.61 to 0.68 | 371 | 0.54 | 0.50 to 0.58 | 324 | 0.59 | 0.55 to 0.62 | |||
| Nuclear grade | < .001 | < .001 | < .001 | ||||||||||
| I, II | 2,831 | 387 | 0.93 | 0.92 to 0.94 | 619 | 0.80 | 0.78 to 0.82 | 571 | 0.82 | 0.80 to 0.84 | |||
| III | 3,671 | 967 | 0.77 | 0.75 to 0.78 | 1,335 | 0.61 | 0.59 to 0.63 | 1,190 | 0.65 | 0.63 to 0.67 | |||
| Lymphovascular invasion | < .001 | < .001 | < .001 | ||||||||||
| Negative | 4,600 | 810 | 0.88 | 0.87 to 0.89 | 1,261 | 0.73 | 0.72 to 0.75 | 1,131 | 0.77 | 0.75 to 0.78 | |||
| Positive | 2,227 | 627 | 0.76 | 0.74 to 0.78 | 874 | 0.59 | 0.57 to 0.61 | 793 | 0.63 | 0.61 to 0.66 | |||
| Type of surgery | < .001 | < .001 | < .001 | ||||||||||
| BCS | 3,042 | 497 | 0.87 | 0.85 to 0.88 | 760 | 0.75 | 0.74 to 0.77 | 671 | 0.78 | 0.76 to 0.80 | |||
| Mastectomy | 3,784 | 940 | 0.82 | 0.80 to 0.83 | 1,374 | 0.64 | 0.62 to 0.65 | 1,253 | 0.68 | 0.66 to 0.69 | |||
| No. of comorbidities | < .001 | < .001 | < .001 | ||||||||||
| 0 | 2,142 | 279 | 0.80 | 0.77 to 0.82 | 779 | 0.45 | 0.42 to 0.49 | 697 | 0.52 | 0.49 to 0.56 | |||
| 1-2 | 2,970 | 728 | 0.85 | 0.84 to 0.87 | 845 | 0.74 | 0.73 to 0.76 | 764 | 0.77 | 0.75 to 0.79 | |||
| 3-4 | 1,387 | 356 | 0.83 | 0.81 to 0.85 | 413 | 0.72 | 0.69 to 0.74 | 374 | 0.75 | 0.72 to 0.77 | |||
| ≥ 5 | 328 | 74 | 0.87 | 0.82 to 0.9 | 98 | 0.72 | 0.67 to 0.77 | 89 | 0.75 | 0.70 to 0.80 | |||
| Hormone receptor–positive patients | 3,834 | 604 | 0.88 | 0.87 to 0.90 | 1,005 | 0.73 | 0.72 to 0.75 | 921 | 0.76 | 0.75 to 0.78 | |||
| TTC, days | .39 | .70 | .54 | ||||||||||
| ≤ 30 | 1,604 | 243 | 0.89 | 0.87 to 0.91 | 410 | 0.74 | 0.71 to 0.76 | 372 | 0.77 | 0.74 to 0.79 | |||
| 31-60 | 1,646 | 263 | 0.88 | 0.86 to 0.90 | 441 | 0.73 | 0.71 to 0.76 | 408 | 0.76 | 0.73 to 0.78 | |||
| ≥ 61 | 584 | 98 | 0.87 | 0.83 to 0.90 | 154 | 0.73 | 0.68 to 0.77 | 141 | 0.75 | 0.71 to 0.79 | |||
| HER2-positive patients | 1,142 | 261 | 0.81 | 0.78 to 0.84 | 368 | 0.64 | 0.61 to 0.68 | 333 | 0.68 | 0.65 to 0.71 | |||
| TTC, days | .58 | .46 | .62 | ||||||||||
| ≤ 30 | 445 | 103 | 0.82 | 0.77 to 0.85 | 145 | 0.64 | 0.59 to 0.69 | 130 | 0.69 | 0.63 to 0.74 | |||
| 31-60 | 493 | 106 | 0.82 | 0.77 to 0.86 | 152 | 0.66 | 0.60 to 0.70 | 139 | 0.69 | 0.63 to 0.73 | |||
| ≥ 61 | 204 | 52 | 0.78 | 0.70 to 0.84 | 71 | 0.61 | 0.53 to 0.69 | 64 | 0.64 | 0.55 to 0.71 | |||
| HER2-positive patients treated with trastuzumab | 591 | 53 | 0.85 | 0.81 to 0.89 | 92 | 0.77 | 0.71 to 0.81 | 84 | 0.78 | 0.73 to 0.83 | |||
| TTC, days | .01 | .37 | .24 | ||||||||||
| ≤ 30 | 233 | 19 | 0.88 | 0.81 to 0.93 | 35 | 0.80 | 0.72 to 0.86 | 34 | 0.82 | 0.74 to 0.87 | |||
| 31-60 | 253 | 17 | 0.87 | 0.79 to 0.92 | 37 | 0.75 | 0.66 to 0.82 | 31 | 0.78 | 0.69 to 0.85 | |||
| ≥ 61 | 105 | 17 | 0.75 | 0.61 to 0.85 | 20 | 0.72 | 0.59 to 0.82 | 19 | 0.7 | 0.56 to 0.81 | |||
| Triple-negative patients | 889 | 299 | 0.65 | 0.61 to 0.68 | 371 | 0.54 | 0.5 to 0.58 | 324 | 0.59 | 0.55 to 0.62 | |||
| TTC, days | .004 | .51 | .55 | ||||||||||
| ≤ 30 | 321 | 92 | 0.70 | 0.64 to 0.76 | 131 | 0.56 | 0.50 to 0.62 | 114 | 0.61 | 0.55 to 0.67 | |||
| 31-60 | 412 | 151 | 0.59 | 0.53 to 0.65 | 174 | 0.52 | 0.47 to 0.58 | 149 | 0.57 | 0.52 to 0.63 | |||
| ≥ 61 | 156 | 56 | 0.67 | 0.57 to 0.75 | 66 | 0.53 | 0.44 to 0.61 | 61 | 0.56 | 0.47 to 0.65 |
Abbreviations: BC, breast cancer; BCS, breast-conserving surgery; DRFS, distant relapse-free survival; HER2, human epidermal growth factor receptor 2; OS, overall survival; RFS, relapse-free survival; TTC, time to initiation of adjuvant chemotherapy.